---
figid: PMC12012316__kjpp-29-3-321-f7
figtitle: Schematic diagram
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC12012316
filename: kjpp-29-3-321-f7.jpg
figlink: /pmc/articles/PMC12012316/figure/F7/
number: F7
caption: The combination treatment of PAN and DOX inhibits cell growth and induces
  apoptosis of CRC cells by targeting the Akt signaling pathway. LY294002 further
  inhibits Akt activity and its downstream functions after treatment with the combination
  of PAN and DOX. CRC, colorectal cancer; PAN, panobinostat; DOX, doxorubicin; p,
  phosphorylated; Gsk3β, glycogen synthase kinase 3β; mTOR, mammalian target of rapamycin;
  P70S6K, ribosomal protein S6 kinase beta-1; SREBP-1, sterol regulatory element-binding
  protein 1; MMP-9, matrix metalloproteinase-9; uPA, urokinase-type plasminogen activator;
  PARP, poly (ADP-ribose) polymerase
papertitle: Enhancing doxorubicin’s anticancer impact in colorectal cancer by targeting
  the Akt/Gsk3β/mTOR-SREBP1 signaling axis with an HDAC inhibitor
reftext: Huaxin Zhao, et al. Korean J Physiol Pharmacol. 2025 May 1;29(3).
year: '2025'
doi: 10.4196/kjpp.24.274
journal_title: 'The Korean Journal of Physiology & Pharmacology : Official Journal
  of the Korean Physiological Society and the Korean Society of Pharmacology'
journal_nlm_ta: Korean J Physiol Pharmacol
publisher_name: Korean Physiological Society and Korean Society of Pharmacology
keywords: c-Myc | Colorectal neoplasms | Doxorubicin | Panobinostat | Proto-Oncogene
  Proteins c-akt/ | glycogen synthase kinase-3 beta/ mammalian target of rapamycin
  | Sterol regulatory element binding | protein 1
automl_pathway: 0.9585037
figid_alias: PMC12012316__F7
figtype: Figure
redirect_from: /figures/PMC12012316__F7
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC12012316__kjpp-29-3-321-f7.html
  '@type': Dataset
  description: The combination treatment of PAN and DOX inhibits cell growth and induces
    apoptosis of CRC cells by targeting the Akt signaling pathway. LY294002 further
    inhibits Akt activity and its downstream functions after treatment with the combination
    of PAN and DOX. CRC, colorectal cancer; PAN, panobinostat; DOX, doxorubicin; p,
    phosphorylated; Gsk3β, glycogen synthase kinase 3β; mTOR, mammalian target of
    rapamycin; P70S6K, ribosomal protein S6 kinase beta-1; SREBP-1, sterol regulatory
    element-binding protein 1; MMP-9, matrix metalloproteinase-9; uPA, urokinase-type
    plasminogen activator; PARP, poly (ADP-ribose) polymerase
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - AKT1
  - AKT2
  - AKT3
  - PARP1
  - COL11A2
  - PARP2
  - PARP3
  - PARP4
  - PARP6
  - PARP8
  - PARP9
  - PARP10
  - PARP11
  - PARP12
  - PARP14
  - PARP15
  - PARP16
  - TNKS
  - TNKS2
  - TIPARP
  - MMP9
  - PLAU
  - PRAP1
  - GSK3A
  - GSK3B
  - MTOR
  - RPS6KB1
  - RPS6KB2
  - SREBF1
  - PARP
  - Nucleus
---
